NVS
Novartis AG
PE ratio, current and historical analysis
- Stocks
- Healthcare
- NYSE: NVS
- PE Ratio
As of Aug 21, 2026, the Novartis AG stock's PE ratio is 23.85. This results from the current EPS of $6.66 and stock price of $158.86. The PE ratio has increased by 17% from the past four quarters average of 20.5.
NVS PE ratio history
The PE ratio of Novartis AG has averaged 20.01 over the last ten years. The current price-to-earnings ratio of 23.85 is 19% more than the historical average. In the past ten years, NVS's PE ratio reached its highest point in the Jun 2017 quarter at 30.35, when the stock price was $83.47 and the EPS was $2.75. The lowest point was recorded in the Sep 2022 quarter, when it reached 7.77 with a price of $76.01 and an EPS of $9.78.
Novartis AG PE ratio by year
Maximum annual increase: 248.1% in 2022
Maximum annual decrease: -69.29% in 2021
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| 2025 | 19.12 | 16.3% | $137.87 | $7.21 |
| 2024 | 16.44 | 16.43% | $97.31 | $5.92 |
| 2023 | 14.12 | -50.35% | $100.97 | $7.15 |
| 2022 | 28.44 | 248.1% | $90.72 | $3.19 |
| 2021 | 8.17 | -69.29% | $87.47 | $10.71 |
| 2020 | 26.6 | 43.86% | $94.43 | $3.55 |
| 2019 | 18.49 | 17.25% | $94.69 | $5.12 |
| 2018 | 15.77 | -38.4% | $85.81 | $5.44 |
| 2017 | 25.6 | -0.89% | $83.96 | $3.28 |
| 2016 | 25.83 | 122.1% | $72.84 | $2.82 |
| 2015 | 11.63 | -47.16% | $86.04 | $7.4 |
| 2014 | 22.01 | 2.95% | $92.66 | $4.21 |
| 2013 | 21.38 | 29.34% | $80.38 | $3.76 |
| 2012 | 16.53 | 8.39% | $63.3 | $3.83 |
| 2011 | 15.25 | 10.75% | $57.17 | $3.75 |
Novartis AG PE ratio by quarter (TTM)
| Year | PE ratio | PE change | Price | EPS |
|---|---|---|---|---|
| Jun 2026 | 23.53 | 8.13% | $156.72 | $6.66 |
| Mar 2026 | 21.76 | 13.81% | $152.75 | $7.02 |
| Dec 2025 | 19.12 | 9.76% | $137.87 | $7.21 |
| Sep 2025 | 17.42 | -0.68% | $128.24 | $7.36 |
| Jun 2025 | 17.54 | 1.15% | $121.01 | $6.9 |
| Mar 2025 | 17.34 | 5.47% | $111.48 | $6.43 |
| Dec 2024 | 16.44 | 22.78% | $97.31 | $5.92 |
| Sep 2024 | 13.39 | -1.11% | $115.02 | $8.59 |
| Jun 2024 | 13.54 | 3.2% | $106.46 | $7.86 |
| Mar 2024 | 13.12 | -7.08% | $96.73 | $7.37 |
| Dec 2023 | 14.12 | -48.16% | $100.97 | $7.15 |
| Sep 2023 | 27.24 | -2.3% | $101.86 | $3.74 |
| Jun 2023 | 27.88 | -0.61% | $100.91 | $3.62 |
| Mar 2023 | 28.05 | -1.37% | $92 | $3.28 |
| Dec 2022 | 28.44 | 266.02% | $90.72 | $3.19 |
NVS Price vs fair value
NVS average PE ratio chart
What this chart measures
The Historical Valuation Regime chart shows where the stock's current valuation sits relative to its own historical valuation range over the selected lookback period.
This is a history-relative tool, not a market-relative percentile. It does not compare the stock to other companies. Instead, it compares each historical valuation reading to the stock's own past readings.
Percentile logic
The threshold lines are calculated them from the stock's real historical values using percentile interpolation. That is why some colored bands are narrow while others are wide: the band widths reflect how the stock actually traded through time.
Regime map
| Historical percentile | Regime | Chart meaning |
|---|---|---|
| 0-10 | Historically Low | Deep cheap zone |
| >10-25 | Below Average | Cheap relative to history |
| >25-75 | Average | Within the normal historical range |
| >75-90 | Above Average | Expensive relative to history |
| >90-100 | Historically High | Extreme or stretched valuation |
How to read each part
| Chart element | What it tells you |
|---|---|
| Main line | The actual historical valuation values over time for the selected metric. |
| Dashed horizontal lines | The stock's computed P10, P25, Median, P75, and P90 thresholds for the selected period. |
| Colored bands | The historical valuation zones between those thresholds. |
| Metric boxes | Current ratio, historical median, current percentile, and current regime. |
| Timeline strip | A condensed regime history showing how the stock moved between cheap, fair, and expensive states across each observation. |
Important metric definitions
Current Percentile is the percentile rank of the latest valid historical observation within the selected lookback range.
Current Regime is assigned directly from the latest observation's percentile bucket using the fixed 10 / 25 / 75 / 90 cutoffs shown above.
How to use it well
This chart is most useful for answering a narrow question: Is this stock trading high, low, or normal relative to its own history? It works best alongside growth, profitability, and forward-looking business analysis, because a stock can deserve a higher or lower regime if its business quality has changed.
The current PE ratio of NVS is above its 3, 5 and 10-year historical averages.
PE comparison
With a P/E of 23.85, NVS stands below the Healthcare sector, the industry and its peers average. But when looking at its Healthcare sector average of 24.52, Novartis AG's P/E is only 2.7% lower.
NVS PE vs peers
Frequently asked questions
What is Novartis AG's PE ratio?
NVS stock has a price to earnings ratio of 23.85 as of Aug 21, 2026.
What is the 3-year average PE ratio for Novartis AG (NVS)?
The 3-year average PE ratio for NVS stock is 17.88.
What is the 5-year average PE ratio for Novartis AG (NVS)?
The 5-year average PE ratio for NVS stock is 17.5.
What is the highest PE ratio for NVS?
Over the last ten years, the quarterly PE ratio reached a historic high of 30.35 in the Jun 2017 quarter.
How does the current PE ratio for NVS compare to its historical average?
NVS's price to earnings ratio is currently 19% above its 10-year historical average.
How is NVS's PE ratio calculated (Novartis AG PE ratio formula)?
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Aug 21, 2026), Novartis AG's stock price is $158.86. The earnings per share for the trailing twelve months (TTM) ending Jun 2026 is $6.66. Therefore, Novartis AG's price to earnings ratio for today is 23.85. PE RATIO(23.85) = STOCK PRICE($158.86) / TTM EPS($6.66)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.